Disopyramide-induced ventricular tachycardia.
A patient with ischemic cardiomyopathy and congestive heart failure was treated with disopyramide phosphate for ventricular arrhythmias. The development of ventricular tachycardia was associated with elevated plasma disopyramide levels and prolongation of the QRS and QT intervals, suggesting a disopyramide-induced depression of ventricular conduction and a prolongation of recovery. Thus, in patients with congestive heart failure, as well as in patients with renal and/or hepatic dysfunction, special care must be exercised with respect to the use of disopyramide.
D000437:Alcoholism / Q000150:complications; D005117:Cardiac Complexes, Premature / Q000188:drug therapy; D009202:Cardiomyopathies / Q000150:complications; D003327:Coronary Disease / Q000150:complications; D004206:Disopyramide / Q000009:adverse effects* / Q000097:blood / Q000627:therapeutic use; D006333:Heart Failure / Q000097:blood / Q000150:complications; D006352:Heart Ventricles; D006801:Humans; D008297:Male; D008875:Middle Aged; D011725:Pyridines / Q000009:adverse effects*; D013610:Tachycardia / Q000097:blood / Q000139:chemically induced*
D011725:Pyridines; D004206:Disopyramide